Cannabics Pharmaceuticals Competitors

Cannabics Pharmaceuticals (OTCMKTS:CNBX) and Innovative Industrial Properties (NYSE:IIPR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Cannabics Pharmaceuticals and Innovative Industrial Properties' revenue, earnings per share (EPS) and valuation.

Innovative Industrial Properties has higher revenue and earnings than Cannabics Pharmaceuticals.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Cannabics Pharmaceuticals and Innovative Industrial Properties, as provided by MarketBeat.com.

Innovative Industrial Properties has a consensus target price of $192.4286, indicating a potential upside of 1.82%. Given Innovative Industrial Properties' higher probable upside, analysts clearly believe Innovative Industrial Properties is more favorable than Cannabics Pharmaceuticals.

Institutional & Insider Ownership

74.9% of Innovative Industrial Properties shares are owned by institutional investors. 2.9% of Innovative Industrial Properties shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Cannabics Pharmaceuticals and Innovative Industrial Properties' net margins, return on equity and return on assets.

Summary

Innovative Industrial Properties beats Cannabics Pharmaceuticals on 8 of the 8 factors compared between the two stocks.

GrowGeneration (NASDAQ:GRWG) and Cannabics Pharmaceuticals (OTCMKTS:CNBX) are both basic materials companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Insider & Institutional Ownership

51.3% of GrowGeneration shares are held by institutional investors. 13.6% of GrowGeneration shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares GrowGeneration and Cannabics Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for GrowGeneration and Cannabics Pharmaceuticals, as provided by MarketBeat.com.

GrowGeneration currently has a consensus price target of $49.5714, indicating a potential downside of 8.24%. Given GrowGeneration's higher possible upside, equities research analysts clearly believe GrowGeneration is more favorable than Cannabics Pharmaceuticals.

Earnings and Valuation

This table compares GrowGeneration and Cannabics Pharmaceuticals' gross revenue, earnings per share and valuation.

GrowGeneration has higher revenue and earnings than Cannabics Pharmaceuticals.

Summary

GrowGeneration beats Cannabics Pharmaceuticals on 8 of the 8 factors compared between the two stocks.

Cannabics Pharmaceuticals (OTCMKTS:CNBX) and 22nd Century Group (NYSEAMERICAN:XXII) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Cannabics Pharmaceuticals and 22nd Century Group, as reported by MarketBeat.

Earnings & Valuation

This table compares Cannabics Pharmaceuticals and 22nd Century Group's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Cannabics Pharmaceuticals and 22nd Century Group's net margins, return on equity and return on assets.

Summary

22nd Century Group beats Cannabics Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

KushCo (OTCMKTS:KSHB) and Cannabics Pharmaceuticals (OTCMKTS:CNBX) are both multi-sector conglomerates companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Insider and Institutional Ownership

0.0% of KushCo shares are held by institutional investors. 17.3% of KushCo shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for KushCo and Cannabics Pharmaceuticals, as reported by MarketBeat.

KushCo presently has a consensus price target of $1.8750, indicating a potential upside of 45.35%. Given KushCo's higher possible upside, analysts clearly believe KushCo is more favorable than Cannabics Pharmaceuticals.

Earnings and Valuation

This table compares KushCo and Cannabics Pharmaceuticals' gross revenue, earnings per share and valuation.

Cannabics Pharmaceuticals has lower revenue, but higher earnings than KushCo.

Profitability

This table compares KushCo and Cannabics Pharmaceuticals' net margins, return on equity and return on assets.

Summary

KushCo beats Cannabics Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

NSAV (OTCMKTS:NSAV) and Cannabics Pharmaceuticals (OTCMKTS:CNBX) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Valuation & Earnings

This table compares NSAV and Cannabics Pharmaceuticals' gross revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for NSAV and Cannabics Pharmaceuticals, as reported by MarketBeat.com.

Profitability

This table compares NSAV and Cannabics Pharmaceuticals' net margins, return on equity and return on assets.

Terra Tech (OTCMKTS:TRTC) and Cannabics Pharmaceuticals (OTCMKTS:CNBX) are both industrial products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Profitability

This table compares Terra Tech and Cannabics Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Terra Tech and Cannabics Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Cannabics Pharmaceuticals has lower revenue, but higher earnings than Terra Tech.

Insider & Institutional Ownership

0.1% of Terra Tech shares are held by institutional investors. 6.7% of Terra Tech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Terra Tech and Cannabics Pharmaceuticals, as reported by MarketBeat.com.